[Development and status of personalized medicine in Germany].
Medical treatment and disease prevention do not affect all people in the same way. Personalized medicine (PM) strives to take into consideration treatment-relevant differences between humans, for example, to improve the efficacy of medicines and to reduce side effects. In Germany, the number of approved active substances for which a biomarker test is obligatory or recommended before use has doubled in the past five years. Applications of drugs with a companion diagnostic test are often referred to as PM in a narrow sense and lie predominantly in the field of cancer therapy.